Markrete Krikorian

About Markrete Krikorian

I am a formulation and drug delivery leader focused on advancing RNA therapeutics and non-viral delivery platforms through clear strategy, translational judgment, and cross-functional integration. Trained at MIT, I have deep experience linking material properties to in vivo performance across lipid nanoparticles, controlled-release polymers, and protein-based biomaterials.My work centers on helping teams make better delivery decisions earlier by integrating chemistry, analytical insight with biological context, manufacturability, and regulatory considerations. I have led formulation and analytical strategy for LNP-based gene editing programs, working closely with biology, tox, and CMC teams from concept through in vivo evaluation. I have also built formulation, stability, and scalability strategies for novel delivery platforms at prior roles.Through my company, Next Phase Analytix, I now partner with biotech and research teams to clarify delivery tradeoffs, define decision-ready formulation frameworks, and reduce development risk in early and translational programs.

Experience

1. Founder & Principal Consultant

   Next Phase Analytix

   Jul 2025 — Present · MA, US

   I advise biotech teams on delivery platform strategy across modalities, with a focus on lipid nanoparticles, polymer systems, and hybrid delivery approaches. Engagements typically involve clarifying delivery tradeoffs, interpreting data in a translational context, and helping teams make informed go or no-go decisions aligned with clinical and regulatory realities and goals.Representative work includes-Defining delivery strategy and platform selection for gene editing and nucleic acid therapeutics-Translational assessment of delivery performance, tolerability, and risk-CMC strategy development including material control, comparability, and vendor oversight-Supporting regulatory interactions by framing delivery and formulation decisions clearly and defensiblyCurrently supporting N=1 accelerated therapeutic timeline for gene editing delivery in the lung

Education

• Massachusetts Institute of Technology

  Doctor of Philosophy - PhD, Chemistry (Materials and Surfaces)

  2011 — 2017

• Columbia University

  Bachelor's degree, Chemistry

  2007 — 2011